Hepatocellular carcinoma (HCC) is a common cancer with a dismal prognosis. Although partial hepatectomy is the most widely practiced form of therapy aiming at cure, the tumour resectability at diagnosis is low. The rate of tumour recurrence after operation is high, which ranges from 60% to 100% at 5 years ([@bib28]; [@bib14]; [@bib38]). There is still no effective means to predict tumour recurrence after partial hepatectomy. Although risk factors associated with post-operative HCC recurrence have been identified, the heterogeneity of HCC renders early detection of post-operative tumour recurrence a major challenge.

Alpha-[L]{.smallcaps}-fucosidase (AFU), a liposomal enzyme present in all mammalian cells and involved in the degradation of a variety of fucose-containing fucoglycoconjugates, has been proposed as a promising tumour marker in the diagnosis of HCC ([@bib11]; [@bib20]). Alpha-[L]{.smallcaps}-fucosidase has been suggested to be able to diagnose 85% of patients with HCC 6 months before the detection by ultrasonography ([@bib12]). Although some studies suggested that AFU can be used to detect recurrent HCC after interventional therapies ([@bib26]; [@bib15]), the use of preoperative serum AFU as a clinical prognostic predictor of HCC has not been reported.

In the first part of this study, a retrospective study was conducted on a group of patients who received partial hepatectomy for HCC to determine the best cut-off value of preoperative serum AFU to be used as a prognostic indicator to determine long-term recurrence-free survival (RFS) and overall survival (OS) after surgery. The cut-off value of this training cohort for AFU was then applied to an independent prospective cohort at the second stage of the study to validate the prognostic value of AFU (the validation cohort) on the RFS and OS after surgery.

Materials and Methods
=====================

Patients and design
-------------------

From 2002 to 2010, all patients who underwent partial hepatectomy for HCC at the Eastern Hepatobiliary Surgery Hospital in Shanghai were considered to be included into this study. The data of patients from 2002 to 2007 were collected retrospectively and were used for the training cohort. The patients since 2008--2010 were recruited in a prospective study and were used as the validation cohort. Only patients who met the following criteria were included: (1) no previous treatment for HCC, (2) no other malignancies, (3) undergoing curative resection, defined as complete macroscopic removal of the tumour ([@bib30]), (4) HCC was confirmed histologically in the resected specimens.

The tumour stage was determined according to the Barcelona Clinic Liver Cancer (BCLC) staging system ([@bib6]). Written informed consent was obtained from all the patients. The study was approved by the Ethics Committee of the Eastern Hepatobiliary Surgery Hospital.

Serum AFU activity
------------------

Serum AFU activity was measured as previously described ([@bib29]) using 7600 Clinical Analyzer made by Hitachi High-Technologies (Tokyo, Japan). The AFU test kit was from BQKITS (catalogue number: BQ082A-EALD). Serum from all fasting subjects were stored at −20 °C and assayed within 30 days after collection because AFU activity levels are known to decrease after this period ([@bib44]).

Follow-up and survival analyses
-------------------------------

Post-operative patient surveillance was performed as described previously ([@bib42]). A diagnosis of recurrence was based on computed tomography and/or magnetic resonance imaging, digital subtraction angiography and raised serum *α*-fetoprotein (AFP) level, with or without histological confirmation. When recurrent HCC was diagnosed, the patients were actively treated with radiofrequency ablation, percutaneous ethanol injection, transarterial chemoembolisation or repeat liver resection, according to the general condition of the patient, the underlying liver functional status and the number and location of HCC recurrence. Recurrence-free survival was defined as the interval (in months) between partial hepatectomy and the diagnosis of HCC recurrence ([@bib24]), using either intrahepatic recurrence or extrahepatic metastasis as end points ([@bib43]). Overall survival was defined as the interval (in months) from the date of partial hepatectomy to the date of the death ([@bib43]). This study was censored on 31 December 2012.

Statistical analyses
--------------------

The cut-off prognostic value for OS obtained in the training cohort was estimated by the X-tile 3.6.1 software (Yale University, New Haven, CT, USA) ([@bib7]; [@bib36]). The receiver operating characteristic analysis confirmed this level to be the optimal cut-off. It was, therefore, used in the analyses for the validation cohort.

A total of 15 clinical pathologic and biological variables were selected for further analysis. The differences in the categorical variables were evaluated using chi-square test between the training cohort and the validation cohort. Fisher\'s exact probability test was used to compare the dynamic changes of AFU levels after surgery. Survival was analyzed by the Kaplan--Meir method and survival curves were compared by the log-rank test. Univariate and multivariate analyses were based on the Cox proportional. Spearman correlation coefficient was used to determine significant correlations among AFU level and AFP level. A value of *P*\<0.05 was considered statistically significant. The analysis was performed with the SPSS for Windows 20.

Results
=======

Patient characteristics
-----------------------

From 2002 to 2007 (the training cohort period), there were 520 patients who received partial hepatectomy for HCC in our centre. The corresponding figure for 2008--2010 (the validation cohort period) was 222 patients. After exclusion, 669 patients were finally enrolled in the analysis (459 and 210 in the training cohort and the validation cohort, respectively). The following patients were excluded from the final analysis: not meeting all the inclusion criteria (16 and 9 for the training cohort and the validation cohort, respectively), lost to follow-up (25 and 0 for the training cohort and the validation cohort, respectively), unevaluable AFU (20 and 0 for the training cohort and the validation cohort, respectively), refusal to take part in the research (3 for the validation cohort). The flow chart is shown in [Figure 1](#fig1){ref-type="fig"}.

The characteristics of the participants in the training and the validation cohorts are shown in [Table 1](#tbl1){ref-type="table"} and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. There was no significant difference in age and sex between the training and validation cohorts. In the training cohort, there were more patients with hepatitis B surface antigen (HBsAg) positivity than in the validation cohort (92.4% *vs* 85.7%, respectively; *P*=0.011). In the validation cohort, there were significantly fewer patients with alanine aminotransferase, or ALT\>44 u l^−1^ than in the training cohort (44.3% *vs* 56.5%, respectively; *P*=0.005). Serum AFP level was well balanced between the training and validation cohorts. There were fewer patients with AFU \>35 u l^−1^ in the training cohort than in the validation cohort (40.3% *vs* 52.4%, respectively; *P*=0.004). The tumour characteristics, such as tumour size, tumour number, presence/absence of macrovascular invasion, BCLC stages were similar between the two cohorts.

The cut-off prognostic value for AFU
------------------------------------

The cut-off prognostic value for OS obtained in the training cohort was estimated by the X-tile 3.6.1 software (Yale University, New Haven, CT, USA) ([@bib7]; [@bib36]), The results indicated a serum AFU value of 35 u l^−1^ to have the most significant predicting value on OS (*P*\<0.0001, log-rank chi-square value=63.6758, relative risks of AFU⩽35 u l^−1^/AFU\>35 u l^−1^, 1.0/1.44; [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

Survival analysis
-----------------

On the day this study was censored, 601 patients had developed tumour recurrence (*n*=447, or 97.4% and *n*=154, or 73.3% for the training cohort and the validation cohort, respectively), 406 patients had died of HCC (*n*=342, or 74.5% and *n*=64, or 30.5% for the training cohort and the validation cohort, respectively), whereas 195 patients were surviving but with HCC disease and 68 patients were surviving without the disease. The median follow-ups were 38.6 months (95% confidence interval (CI), 33.4--43.1 months) and 30.8 months (95% CI, 28.0--33.3 months) for the training cohort and the validation cohort, respectively. The 1- and 3-year RFS rates were 44.9%, 10.7% for the training cohort, and 48.5%, 26.2% for the validation cohort. The 1- and 3-year OS were 81.9%, 53.4% for the training cohort and 83.8%, 69.6% for the validation cohort, respectively. The 5-year RFS and OS for the training cohort were 3.1% and 32.2%, respectively. The follow-up was too short to determine the 5-year RFS and OS for the validation cohort ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

On univariate analysis of the training cohort and the validation cohort, and/or on Cox\'s multivariate analysis by merging the two data sets ([Table 2](#tbl2){ref-type="table"}, [Supplementary Tables S2 and S3](#sup1){ref-type="supplementary-material"}), the preoperative AFU level was an independent risk factor of post-operative RFS and OS (*P*=0.001; hazard ratio (HR): 1.369; 95% CI: 1.134--1.653 and *P*\<0.001; HR: 1.724; 95% CI: 1.376--2.160 for RFS and OS, respectively).

Alpha-[L]{.smallcaps}-fucosidase in the prediction of prognosis in the training cohort
--------------------------------------------------------------------------------------

By comparing the AFU expression levels between the normal expression group and the elevated group, the cumulative 1-, 3- and 5-year RFS rates were 56.6%, 16.8% and 5.1%, respectively, in patients who had a normal AFU expression (⩽35 u l^−1^) in the training cohort. The 1-, 3-year RFS rate was 27.6% and 1.6%, respectively (*P*\<0.001; [Figure 2A](#fig2){ref-type="fig"}) in the group of patients with AFU \>35 u l^−1^. The cumulative 1-, 3- and 5-year OS rates were 85.8%, 66.8%, 44.2% and 76.2%, 33.5%, 14.6% for the AFU normal group and the AFU elevated group, respectively, in the training cohort (*P*\<0.001 [Figure 2B](#fig2){ref-type="fig"}).

On univariate analysis in the training cohort using Cox\'s multivariate analysis ([Table 2](#tbl2){ref-type="table"}). AFU was an independent risk factor of RFS and OS (*P*\<0.001; HR: 1.738; 95% CI: 1.383--2.185 and *P*\<0.001; HR: 1.814; 95% CI: 1.421--2.315 for RFS and OS, respectively).

Alpha-[L]{.smallcaps}-fucosidase in the prediction of prognosis in the validation cohort
----------------------------------------------------------------------------------------

Similar results were obtained in the validation cohort. The cumulative 1-, 3-year RFS rates were 57.0, 30.0% and 40.8, 22.8% for the AFU normal group and the AFU elevated group, respectively (*P*=0.041; [Figure 2C](#fig2){ref-type="fig"}). The 1-, 3-year OS rates were 76.4%, 57.1% and 92.0%, 83.6% for the AFU elevated group and the normal group, respectively (*P*\<0.001; [Figure 2D](#fig2){ref-type="fig"}). Alpha-[L]{.smallcaps}-fucosidase was an independent risk factor of OS (*P*=0.008; HR: 2.333; 95% CI: 1.249--4.369) ([Table 2](#tbl2){ref-type="table"}).

Dynamic changes in AFU levels after surgery
-------------------------------------------

The post-operative AFU levels were measured in the validation cohort on days 1, 3, 5 and 1 month following partial hepatectomy. The preoperative elevated levels of AFU \>35 u l^−1^ dropped dramatically after surgery (100%, *n*=110 to 13.6%, *n*=15, *P*\<0.001; [Figure 3A](#fig3){ref-type="fig"}) at 1 month. For the patients with preoperative normal AFU (⩽35 u l^−1^), there were 4.0% patients who developed high AFU levels (\>35 u l^−1^, 0%, *n*=0 to 4.0%, *n*=4, *P*=0.121; [Figure 3B](#fig3){ref-type="fig"}) at 1 month. The number of patients who had elevated AFU levels was significantly higher in the group of patients with preoperative elevated AFU (\>35 u l^−1^) who had developed recurrence than the group of patients who had not developed recurrence (90.48%, *n*=76 *vs* 19.20%, *n*=5, *P*\<0.001; [Figure 3C](#fig3){ref-type="fig"}). There was no significant difference in the AFU levels between the patients who had developed recurrence or not in those patients who had preoperative normal AFU levels ⩽35 u l^−1^ (18.60%, *n*=13 *vs* 13.30%, *n*=4, *P*=0.772; [Figure 3D](#fig3){ref-type="fig"}).

Preoperative AFU levels in the prediction of macrovascular invasion
-------------------------------------------------------------------

The prognostic significance of preoperative AFU in the prediction of the presence of macrovascular invasion was investigated. Patients with evaluated AFU (\>35 u l^−1^) had a higher incidence of macrovascular invasion (25.0%, *n*=50 *vs* 5.8%, *n*=15, *P*\<0.001 and 18.2%, *n*=20 *vs* 5.0%, *n*=5, *P*=0.005 in the training cohort and the validation cohort, respectively; [Figure 3E and F](#fig3){ref-type="fig"}).

The correlation between AFU level and AFP level
-----------------------------------------------

By analysing the correlation between AFU level and AFP level, we found AFU level was positively correlated with the level of AFP (*r*=0.246, *P*\<0.001 and *r*=0.254, *P*\<0.001 for training cohort and the validation cohort, respectively; [Figure 3G and H](#fig3){ref-type="fig"}), the positive rate of AFU in patients with AFP⩽400 ng ml^−1^ was 30.6% (76/248) and 46.0% (57/124) for training cohort and validation cohort, respectively ([Figure 3I](#fig3){ref-type="fig"}).

Prognostic significance of preoperative AFU in the clinical subgroups
---------------------------------------------------------------------

The prognostic significance of preoperative AFU in the clinical subgroups was investigated by merging the training cohort data and the validation data. In patients with AFP ⩽400 ng ml^−1^, patients with an AFU \>35 u l^−1^ had a shorter time to recurrence (median of 6.51 months *vs* 16.59 months, *P*\<0.001; [Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}) and a lower survival rate (33.1%,*n*=91 *vs* 55.4%, *n*=189, *P*=0.004; [Supplementary Figure S4G](#sup1){ref-type="supplementary-material"}) with shorter time to death (median of 27.2 months *vs* 42.94 months, *P*\<0.001; [Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}) than those patients with AFU⩽35 u l^−1^. Similar results were obtained in the other low recurrence risk subgroups including those subgroups with a tumour size of ⩽5 cm, absence of macrovascular invasion, gamma-glutamyl transpeptidase (GGT)⩽64 u l^−1^, and a BCLC stage of 0+A ([Supplementary Figures S3B--G](#sup1){ref-type="supplementary-material"} and [S4B--G](#sup1){ref-type="supplementary-material"}).

The prognostic significances of the preoperative AFU for patients with AFP ⩽20 ng ml^−1^, tumour size ⩽5 cm, single tumour and absence of macrovascular invasion were investigated, and the results showed AFU to have significant prognostic values for these subgroups of patients in both RFS and OS ([Supplementary Figure S5A and B](#sup1){ref-type="supplementary-material"}).

Discussion
==========

This study depicts not only that a preoperative AFU level of ⩽35 u l^−1^ is a prognostic indicator associated with RFS and OS but also that it is an important prognostic indicator for clinical subgroups of patients who have a low risk of tumour recurrence and tumour-related death, including those patients who have an AFP ⩽400 ng ml^−1^, a tumour size of ⩽5 cm, a GGT ⩽64 u l^−1^, a single tumour, a BCLC stage of 0+A, and those patients absence of macrovascular invasion. Although AFU measurement has been used for the diagnosis of HCC for many years, this study provides the first evidence for the use of preoperative AFU in predicting post-hepatectomy RFS and OS. The study showed that a preoperative AFU⩽35 u l^−1^ is predictive of better survival and supports the use of preoperative AFU level in monitoring treatment outcomes of HCC.

AFU is a lysosomal enzyme present in all mammalian cells. It is involved in the catabolism of fucose-containing glycoconjugates ([@bib10]). The use of serum AFU for the early diagnosis of HCC has previously been reported ([@bib17]; [@bib37]; [@bib5]; [@bib16]), but the mechanism of elevation of serum AFU activity in HCC patients has not been determined. One possibility is an increase in protein synthesis by the neoplasm with a consequent increase in fucose turnover ([@bib11]). However, this possibility was not supported by reports showing a significantly lower AFU level in HCC tissue compared with paired non-tumorous liver tissue ([@bib20]; [@bib18]), which suggests that an elevated serum level of AFU was not directly derived from tumour cells ([@bib5]). The AFU elevation in tumour liver tissue may be a result of the decrease in enzyme degradation. Sialic acid of glycoproteins has a strong influence on its clearance rate in blood circulation, and it is possible that its change results in retarded clearance of the glycoproteins ([@bib27]; [@bib2]; [@bib18]).

In this study, we focused on the correlation of preoperative AFU level with clinical outcomes. There have been some previous observational studies on the increase in serum AFU in breast cancer patients with progressive disease, followed by a decrease with successful therapy ([@bib39]). Another study also shows that the mean value of preoperative serum AFU activity was higher in colorectal cancer (CRC) patients with distant metastases than in those with lymph node or peritoneal metastases, or without metastasis. The measurement of preoperative serum AFU activity could serve to detect hidden metastases for CRC, even before surgical intervention ([@bib3]). Most of the CRC patients with distant metastasis, for example, hepatic metastasis have a higher serum AFU level probably due to a greater flux of the enzyme from the malignant liver tissue to extracellular fluid ([@bib11]; [@bib37]). Our study showed HCC patients with AFU ⩽35 u l^−1^ had a better prognosis. Liver inflammation has an important role in the pathogenesis of HCC ([@bib25]; [@bib13]). The liver contains various cell types that produce cytokines and chemokines ([@bib19]), and these cytokines and chemokines can upregulate AFU in the later stages of inflammation. This process is consistent with activation of a natural regulatory loop, resulting in a gradual diminution of the potential of blood-borne leukocytes to penetrate the endothelium at the sites of existing inflammation ([@bib1]). This anti-inflammatory/immune-suppressive response may promote HCC metastases.

Compared with before hepatic resection, the AFU activity in patients with AFU\>35 u l^−1^ had a decrease after operation. In about 1 week to 1 month, the AFU activity decreased to normal level. Hence, positive case and positive rate also decreased. It suggests that AFU is a useful marker of HCC for post-treatment monitoring and reminds us much more attention should be taken to the patients who have hold a high AFU expression. For these patients, follow-up treatment and management strategies after operation should be concerned.

Many investigators have reported that total bilirubin, tumour size, GGT and AFP levels are related to a poor prognosis of HCC ([@bib4]; [@bib28]; [@bib34], [@bib35]; [@bib41]). So far, AFP level is the most extensively used diagnostic biomarker and tumour recurrence indicator of HCC in AFP-positive patients ([@bib9]). Clinical data demonstrated that a low serum AFP concentration (e. g. ⩽400 ng ml^−1^) is associated with better clinical outcomes. Nevertheless, it is difficult to monitor recurrence in the 30−40% of HCC patients with low AFP levels ([@bib31]; [@bib40]). Our results indicated the determination of the preoperative AFU level is a promising and feasibly tool for tumour recurrence and death prediction in patients with a low AFP concentration. Another way, we have shown a positively correlation between both AFU level and AFP level. Among the patients with AFP ⩽400 ng ml^−1^, there were 30.6--46.0% patients with AFU \>35 u l^−1^, which may suggest the preoperative AFU level may be more useful for predicting tumour recurrence and death in patients with a low AFP concentration and high AFU level. Macrovascular invasion in patients with HCC is associated with poor survival ([@bib33]; [@bib32]). If left untreated, a median survival of \<6 months has been reported ([@bib23]). Approximately 50--80% of HCC has been reported to be accompanied by portal or hepatic vein tumour thrombus, as demonstrated by magnetic resonance imaging and ultrasonography ([@bib22]). Our result indicated that patients with preoperative serum AFU \>35 u l^−1^ hold a higher incidence of macrovascular invasion than those with AFU ⩽35 u l^−1^, suggesting that there may be a link between AFU and macrovascular invasion.

Chronic hepatitis B virus infection is the most common cause of HCC in Asia ([@bib8]). Chronic hepatitis B virus infection continues to be a major contributor to morbidity and mortality, despite the availability of vaccination programs in China and elsewhere ([@bib21]). Our study limited to test the results in cohorts of patients with hepatitis C- or alcohol-related HCC. Moreover, our study has yet to be validated across the patients who received liver transplantation.

In conclusion, the preoperative serum AFU activity is a predictor of prognosis after hepatic resection for HCC. Patients with preoperative serum AFU \>35 u l^−1^ have a tendency to form macrovascular invasion.
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![**Study flow chart: inclusion criteria, exclusion criteria, and outcome.**](bjc2014102f1){#fig1}

![**Kaplan--Meier analysis for RFS and OS in HCC patients with AFU ⩽35 u l^−1^ or \>35 u l^−1^ preoperatively.** (**A**) RFS in training cohort, (**B**) Overall survival in training cohort, (**C**) RFS in validation cohort, (**D**) OS in validation cohort.](bjc2014102f2){#fig2}

![**Changes in AFU levels reflect treatment response to HCC resection, the link between accompanying macrovascular invasion and AFU levels and the correlation between AFU level and AFP level.** (**A**) Patients with preoperative AFU\>35 u l^−1^ (Fisher\'s exact probability test, *P*\<0.001), (**B**) patients with preoperative AFU\>35 u l^−1^ at the study censored point (chi-square test, *P*\<0.001), (**C**) patients with preoperative AFU⩽ 35 u l^−1^ (Fisher\'s exact probability test, *P*=0.248), (**D**) patients with preoperative AFU⩽35 u l^−1^ at the study censored point (chi-square test, *P*=0.349), (**E**) Patients in training cohort (chi-square test, *P*=0.020) and (**F**) patients in validation cohort (chi-square test, *P*=0.005), (**G**) The correlation between AFU level and AFP level in training cohort, (**H**) the correlation between AFU level and AFP level in validation cohort, (**I**) the positive rate of AFU in patients with AFP⩽400 ng ml^−1^ for training cohort and validation cohort, respectively.](bjc2014102f3){#fig3}

###### Baseline characteristics of study participants in the training and validation data sets

                                 **Training (*****n*****=459)**   **Validation (*****n*****=210)**                
  ------------------------------ -------------------------------- ---------------------------------- ----- ------ -------
  Age (years)                                                                                                     0.451
   ⩽50                           258                              56.2                               111   52.9    
   \> 50                         201                              43.8                               99    47.1    
  Sex                                                                                                             0.259
   Male                          406                              88.5                               179   85.2    
   Female                        53                               11.5                               31    14.8    
  HbsAg                                                                                                           0.011
   Positive                      424                              92.4                               180   85.7    
   Negative                      35                               7.6                                30    14.3    
  Total bilirubin (mmol l^−1^)                                                                                    0.215
   ⩽18.8                         300                              65.4                               148   70.5    
   \> 18.8                       159                              34.6                               62    29.5    
  Albumin (g/l)                                                                                                   0.370
   ⩽34                           19                               4.1                                5     2.4     
   \> 34                         440                              95.9                               205   97.6    
  ALT (u l^−1^)                                                                                                   0.005
   ⩽44                           200                              43.5                               117   55.7    
   \> 44                         259                              56.5                               93    44.3    
  Tumour size (cm)                                                                                                0.108
   ⩽5                            200                              43.6                               77    36.7    
   \> 5                          259                              56.4                               133   63.3    
  Tumour number                                                                                                   0.511
   Single                        425                              92.6                               198   94.3    
   Multiple                      34                               7.4                                12    5.7     
  GGT (u l^−1^)                                                                                                   0.201
   ⩽64                           172                              37.5                               90    42.9    
   \>64                          287                              62.5                               120   57.1    
  AFU (u l^−1^)                                                                                                   0.004
   ⩽35                           274                              59.7                               100   47.6    
   \>35                          185                              40.3                               110   52.4    
  ALP (u l^−1^)                                                                                                   0.062
   ⩽129                          324                              70.6                               163   77.6    
   \>129                         135                              29.4                               47    22.4    
  AFP (ng ml^−1^)                                                                                                 0.241
   ⩽400                          248                              54.0                               124   59      
   \>400                         211                              46.0                               86    41      
  Macrovascular invasion                                                                                          0.466
   Presence                      65                               14.2                               25    11.9    
   Absence                       394                              85.8                               185   88.1    
  Liver cirrhosis                                                                                                 0.764
   Yes                           355                              77.3                               165   78.6    
   No                            104                              22.7                               45    21.4    
  BCLC stages                                                                                                     0.585
   0+A                           375                              81.7                               176   83.8    
   B+C                           84                               18.3                               34    16.2    

Abbreviations: AFP=alpha-fetoprotein; AFU=alpha-fucosidase; ALP=alkaline phosphatase; ALT=alanine aminotransferase; BCLC=Barcelona Clinic Liver Cancer staging system; GGT=*γ*-glutamyl transpeptidase; HbsAg=hepatitis B surface antigen.

Data are number or number (%), unless otherwise indicated.

###### Univariate analysis or multivariate analysis based on the Cox proportional hazard regression model for RFS and OS in patients enrolled in training cohort or validation cohort or Two datasets merging

                                      **Univariate analysis**   **Multivariate analysis**                          
  ----------------------------------- ------------------------- --------------------------- ---------------------- ---------
  **Training cohort---RFS**                                                                                        
  AFU (⩽35 *vs* \>35 u l^−1^)         2.277 (1.864--2.780)      \<0.001                     1.738 (1.383--2.185)   \<0.001
  Tumour size (⩽5 *vs* \>5 cm)        2.055 (1.693--2.494)      \<0.001                     1.663 (1.331--2.079)   \<0.001
  GGT (⩽64 *vs* \>64 u l^−1^)         1.527 (1.258--1.854)      \<0.001                     1.159 (0.933--1.440)   0.183
  AFP (⩽400 *vs* \>400 ng ml^−1^)     1.239 (1.028--1.492)      0.024                       0.905 (0.741--1.106)   0.330
  Macrovascular invasion              1.498 (1.146--1.958)      0.003                       1.248 (0.946--1.646)   0.117
  ALP (⩽129 *vs* \>129 u l^−1^)       1.328 (1.084--1.627)      0.006                       0.998 (0.802--1.241)   0.982
  **Training cohort---OS**                                                                                         
  AFU (⩽35 *vs* \>35 u l^−1^)         2.461 (1.982--3.056)      \<0.001                     1.814 (1.421--2.315)   \<0.001
  Tumour size (⩽5 *vs* \>5 cm)        2.116 (1.692--2.646)      \<0.001                     1.549 (1.208--1.985)   0.001
  GGT (⩽64 *vs* \>64 u l^−1^)         1.788 (1.424--2.247)      \<0.001                     1.159 (0.893--1.504)   0.269
  AFP (⩽400 *vs* \>400 ng ml^−1^)     1.543 (1.247--1.910)      \<0.001                     1.108 (0.883--1.391)   0.376
  Macrovascular invasion              2.444 (1.844--3.240)      \<0.001                     1.893 (1.411--2.539)   \<0.001
  ALP (⩽129 *vs* \>129 u l^−1^)       1.514 (1.209--1.894)      \<0.001                     1.095 (0.859--1.395)   0.463
  TB (⩽18.8 *vs* \>18.8 mmol l^−1^)   1.394 (1.122--1.734)      0.003                       1.354 (1.084--1.692)   0.008
  **Validation cohort---RFS**                                                                                      
  AFU (⩽35 *vs* \>35 u l^−1^)         1.392 (1.013--1.912)      0.041                       0.996 (0.691--1.437)   0.984
  Tumour size (⩽5 *vs* \>5 cm)        1.417 (1.014--1.979)      0.041                       1.047 (0.718--1.527)   0.811
  GGT (⩽64 *vs* \>64 u l^−1^)         1.543 (1.115--2.136)      0.009                       1.373 (0.956--1.974)   0.086
  AFP (⩽400 *vs* \>400 ng ml^−1^)     1.6979 (1.235--2.333)     0.001                       1.533 (1.100--2.137)   0.012
  Macrovascular invasion              3.495 (2.246--5.440)      \<0.001                     2.805 (1.756--4.480)   \<0.001
  **Validation cohort---OS**                                                                                       
  AFU (⩽35 *vs* \>35 u l^−1^)         4.272 (2.446--7.461)      \<0.001                     2.333 (1.249--4.369)   0.008
  Tumour size (⩽5 *vs* \>5 cm)        4.292 (2.246--8.202)      \<0.001                     2.081 (1.019--4.250)   0.044
  GGT (⩽64 *vs* \>64 u l^−1^)         2.765 (1.622--4.712)      \<0.001                     1.500 (0.846--2.661)   0.165
  AFP (⩽400 *vs* \>400 ng ml^−1^)     2.112 (1.329--3.357)      \<0.001                     1.642 (1.022--2.639)   0.040
  Macrovascular invasion              4.615 (2.747--7.754)      \<0.001                     2.352 (1.289--4.289)   0.005
  ALP (⩽129 *vs* \>129 u l^−1^)       2.063 (1.271--3.348)      0.003                       1.095 (0.626--1.915)   0.751
  **Two data sets merging---RFS**                                                                                  
  AFU (⩽35 *vs* \>35 u l^−1^)         1.782 (1.509--2.104)      \<0.001                     1.369 (1.134--1.653)   0.001
  Tumour size (⩽5 *vs* \>5 cm)        1.729 (1.464--2.042)      \<0.001                     1.387 (1.147--1.677)   0.001
  GGT (⩽64 *vs* \>64 u l^−1^)         1.524 (1.291--1.801)      \<0.001                     1.238 (1.028--1.489)   0.024
  AFP (⩽400 *vs* \>400 ng ml^−1^)     1.354 (1.153--1.590)      \<0.001                     1.102 (0.930--1.307)   0.261
  Macrovascular invasion              1.827 (1.453--2.297)      \<0.001                     1.516 (1.195--1.924)   0.001
  ALP (⩽129 *vs* \>129 u l^−1^)       1.244 (1.041--1.487)      0.016                       0.963 (0.795--1.166)   0.700
  **Two data sets merging---OS**                                                                                   
  AFU (⩽35 *vs* \>35 u l^−1^)         2.500 (2.049--3.050)      \<0.001                     1.724 (1.376--2.160)   \<0.001
  Tumour size (⩽5 *vs* \>5 cm)        2.229 (1.808--2.747)      \<0.001                     1.563 (1.239--1.972)   \<0.001
  GGT (⩽64 *vs* \>64 u l^−1^)         1.929 (1.564--2.380)      \<0.001                     1.198 (0.945--1.519)   0.136
  AFP (⩽400 *vs* \>400 ng ml^−1^)     1.664 (1.371--2.020)      \<0.001                     1.238 (1.010--1.518)   0.040
  Macrovascular invasion              2.863 (2.237--3.664)      \<0.001                     2.018 (1.557--2.615)   \<0.001
  ALP (⩽129 *vs* \>129 u l^−1^)       1.636 (1.334--2.007)      \<0.001                     1.158 (0.930--1.442)   0.189
  TB (⩽18.8 *vs* \>18.8 mmol l^−1^)   1.432 (1.173--1.748)      \<0.001                     1.380 (1.127--1.690)   0.002
  Liver cirrhosis (yes *vs* no)       1.326 (1.043--1.687)      0.021                       1.211 (0.949--1.547)   0.124

Abbreviations: A=absence; AFP=alpha-fetoprotein; AFU=alpha-fucosidase; ALP=alkaline phosphatase; 95% CI=95% confidence interval; GGT=*γ*-glutamyl transpeptidase; HR=hazard ratio; OS=overall survival; P=presence; RFS=recurrence-free survival; TB=total bilirubin.

Macrovascular invasion, P *vs* A.

The clinicopathologic variables were adopted for their prognostic significance by univariate analyses.

[^1]: These authors contributed equally to this work.
